Appeals Court Slams FAA’s Psychiatric Certification Practices as “Arbitrary and Capricious”

A major legal victory underscores the FAA’s continued failure to justify its medical certification policies—and highlights exactly why pilots and air traffic controllers must demand transparency and reform.

The U.S. Court of Appeals for the D.C. Circuit has ruled that the FAA’s categorical denial of medical certification to pilots prescribed the antidepressant mirtazapine was “arbitrary and capricious.” The court found that the FAA:

• Failed to provide a clear rationale for its blanket prohibition of mirtazapine in Special Issuance medical certificates.
• Contradicted its own arguments by citing studies inconsistently, ignoring contrary evidence, and failing to show how its policy logically followed from its cited research.
• Relied on thin and variable explanations that did not meet the legal requirement for reasoned decision-making.

In the court’s words, the FAA did not present evidence or reasoning to support its policy and could not rationalize a contradiction between its own statements and the cited studies. This is not just a technical legal error—it reveals how the FAA’s opaque and arbitrary decision-making can derail professional careers without a coherent scientific basis.

What Does This Mean for Pilots and Aviation Professionals?

Although this ruling focused specifically on mirtazapine, the implications reach far beyond one medication:

• The FAA cannot simply wave away due process by repeating unsupported conclusions.
• Any pilot or air traffic controller facing medical denial for prescription treatment should scrutinize the agency’s rationale.
• Future cases will likely build on this decision to challenge categorical policies lacking transparent justification.

As the court made clear, agencies adopting blanket medical bans must present clear evidence and allow for fair evaluation—especially when they impact livelihoods and aviation safety.

A Catalyst for Reform

The Pilots for HIMS Reform community has long argued that the FAA’s Special Issuance process is steeped in secrecy, conflicts of interest, and inconsistent application. This decision validates what many have experienced firsthand:

• The FAA has been applying life-altering decisions without rigorous evidence.
• Professionals are forced into defensive positions to prove their worthiness to fly.
• Pilots’ health and dignity are too often subordinated to bureaucratic inertia.

While this ruling doesn’t set a binding precedent for all medications, it undeniably opens the door to further challenges against unsubstantiated policies—and makes it harder for the FAA to hide behind blanket prohibitions.

Next Steps

If you are currently in the HIMS program or considering seeking a Special Issuance:

• Request the FAA’s complete rationale for any denial or restriction.
• Consult an experienced aviation attorney to determine if the FAA’s position can be challenged.
• Document any inconsistencies in the FAA’s correspondence and medical evaluations.

This is precisely why our movement exists—to shine light on systemic failures and demand an aeromedical process grounded in fairness, evidence, and respect.

Together, We Keep the Pressure On

This victory is a testament to the persistence of advocates, legal teams, and professionals willing to challenge an entrenched system. Every pilot who speaks up or challenges arbitrary decisions moves us closer to lasting change.

We invite you to join us in this effort:

• ✅ Share your story if you’ve experienced similar treatment.
• ✅ Connect with other pilots and controllers who refuse to accept opaque and capricious processes.
• ✅ Support the push for legislative and regulatory reforms to ensure no professional’s career is destroyed by unexamined policies.

The narrative is finally changing—and we are just getting started.